Broad, When you hear the terms CBC and CBD, you might be confused. They are two cannabinoids that act on different receptors in the body. CBC, for example, has a higher chance of interacting with the TRPV1 receptor, which is responsible for inflammatory pain. However, it also interacts with the CB2 receptor.
CBC is a compound found in cannabis that works with other cannabinoids, such as THC and CBD. These plant compounds work together in what’s known as the entourage effect, which amplifies the benefits and effects of each one. For example, CBC is an excellent pain reliever due to its activity on the vanilloid receptor type 1 and the transient receptor potential ankyrin 1 (CRP1), which regulate pain perception. It has also shown the potential to fight acne and other skin inflammations.
Cannabichromene was discovered in 1966 and is the third-most abundant cannabinoid found in cannabis, trailing only THC and CBD. However, it makes up less than 1% of the mass of the Cannabis sativa L. plant. Although it is not available in its natural form in hemp flowers, CBC extracts are available from a few vendors. The concentrations range from ten to fifty mg per serving.
Broad spectrum CBC has a wide variety of benefits, including anti-inflammatory properties, but there are no definitive studies to support its claims. However, it has been shown to improve the performance of neural stem progenitor cells, which play an essential role in maintaining the brain’s internal balance. In addition, CBC can protect neural stem progenitor cells against oxidative and inflammatory stress, which may prevent degenerative brain diseases such as Alzheimer’s. Some studies also suggest that CBC can reduce depression.
Cannabigerol (CBG), a cannabinoid derived from cannabis, has many therapeutic applications. In a study conducted in 2020, CBG was shown to have antibacterial properties. Specifically, it inhibited the activity of methicillin-resistant Staphylococcus aureus or MRSA. In addition, CBG has anti-inflammatory properties and is also helpful in treating glaucoma, a disease caused by the progressive breakdown of nerve cells.
Cannabigerol, like other cannabinoids, works by binding to both anandamide and serotonin receptors. These receptors play essential roles in controlling appetite, sleep, and pain. While CBG does not have psychotropic effects, it is used in various therapeutic applications, including pain management. Although the number of human studies on CBG is still relatively small, it already shows promising results in animal trials.
Cannabigerol and CBD modulate the expression of genes that regulate skin health. CBG stimulates the expression of COL1A1 and COL4A1 cells, which is critical for the skin’s elasticity. In addition, CBG increases the expression of fibronectin and elastin, two essential proteins in skin health. TIMP3 is involved in UVB-induced inflammation, and CBG upregulates these proteins.
Cannabichromene (CB) is a non-psychoactive cannabinoid produced by cannabis plants. It has been shown to promote neurogenesis, or the creation of new brain cells, and has anti-inflammatory properties. It also enhances the effects of other cannabinoids, such as CBD. This non-psychoactive compound works by binding with proteins in the body that are involved in the control of pain and inflammation.
Cannabichromene was discovered in 1966 and is the third most abundant cannabinoid in cannabis, behind THC and CBD. However, it only comprises a tiny portion of the plant mass. It is estimated around 0.3 percent of the plant’s mass. Because of this, it is not readily available in hemp flowers. However, some select vendors make CBC oil tinctures and other consumer products.
Unlike CBD and THC, cannabichromene is a non-psychoactive cannabinoid with numerous health benefits. Although not yet well known, it is a promising compound for treating several health conditions. Studies have shown that cannabichromene can alleviate pain and improve mood while providing neuroprotective properties. Furthermore, it does not produce any side effects.